Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Preprint |
| Published: |
2025
|
| Subjects: | |
| Online Access: | https://arxiv.org/abs/2504.08476 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- The recent development of drugs able to mitigate neurodegenerative diseases has created an urgent need for novel diagnostics. Although biomarker detection directly in patients' blood is now possible, low-cost point-of-care tests remain a challenge, because relevant biomarkers, especially amyloid-β(A$β$) peptides, are small, they occur at very low concentrations, and detecting a single marker is insufficient. Here, we introduce an optical biosensor based on a nanopillar structure that employs a gold nanoparticle amplification strategy. The sensor is able to detect 20 pg/ml of A$β$42 and A$β$40 in undiluted serum, which is the clinically required level. We also show the detection of the A$β$42 and A$β$40 peptides in the same channel, which is highly relevant for assessing disease progress and opens a route towards multiplexing. Alongside their simplicity and portability, these nanotechnology innovations make a major contribution to the ability to detect and monitor the progression of neurodegenerative diseases such as Alzheimer's.